JP4928937B2 - ミグラスタチンアナログおよびその使用 - Google Patents

ミグラスタチンアナログおよびその使用 Download PDF

Info

Publication number
JP4928937B2
JP4928937B2 JP2006509430A JP2006509430A JP4928937B2 JP 4928937 B2 JP4928937 B2 JP 4928937B2 JP 2006509430 A JP2006509430 A JP 2006509430A JP 2006509430 A JP2006509430 A JP 2006509430A JP 4928937 B2 JP4928937 B2 JP 4928937B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
hydrogen
substituted
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006509430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006521407A (ja
JP2006521407A5 (enExample
Inventor
サミュエル ジェイ． ダニシェフスキィ，
クリストフ ガウル，
ヤン ティー． ナーダーソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of JP2006521407A publication Critical patent/JP2006521407A/ja
Publication of JP2006521407A5 publication Critical patent/JP2006521407A5/ja
Application granted granted Critical
Publication of JP4928937B2 publication Critical patent/JP4928937B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
JP2006509430A 2003-03-28 2004-03-26 ミグラスタチンアナログおよびその使用 Expired - Fee Related JP4928937B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45882703P 2003-03-28 2003-03-28
US60/458,827 2003-03-28
US49616503P 2003-08-19 2003-08-19
US60/496,165 2003-08-19
PCT/US2004/009571 WO2004087673A2 (en) 2003-03-28 2004-03-26 Migrastatin analogs and uses thereof

Publications (3)

Publication Number Publication Date
JP2006521407A JP2006521407A (ja) 2006-09-21
JP2006521407A5 JP2006521407A5 (enExample) 2007-06-07
JP4928937B2 true JP4928937B2 (ja) 2012-05-09

Family

ID=33135114

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006509430A Expired - Fee Related JP4928937B2 (ja) 2003-03-28 2004-03-26 ミグラスタチンアナログおよびその使用
JP2006509369A Expired - Fee Related JP4719671B2 (ja) 2003-03-28 2004-03-26 ミグラスタチンアナログ組成物およびその使用
JP2011039073A Withdrawn JP2011105766A (ja) 2003-03-28 2011-02-24 ミグラスタチンアナログ組成物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006509369A Expired - Fee Related JP4719671B2 (ja) 2003-03-28 2004-03-26 ミグラスタチンアナログ組成物およびその使用
JP2011039073A Withdrawn JP2011105766A (ja) 2003-03-28 2011-02-24 ミグラスタチンアナログ組成物およびその使用

Country Status (5)

Country Link
US (4) US7943800B2 (enExample)
EP (2) EP1608626A1 (enExample)
JP (3) JP4928937B2 (enExample)
CA (2) CA2520732C (enExample)
WO (2) WO2004087673A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037783A1 (en) * 2003-03-28 2007-02-15 Xin-Yun Huang Migrastatin analogs and uses thereof
JP4928937B2 (ja) 2003-03-28 2012-05-09 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ ミグラスタチンアナログおよびその使用
JP5149001B2 (ja) * 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
WO2006000923A2 (en) * 2004-06-03 2006-01-05 Novimmune Sa Macrolide compositions as therapeutic agent
CA2582766C (en) * 2004-09-23 2014-07-22 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
ES2435454T3 (es) * 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
WO2009110938A2 (en) * 2007-12-10 2009-09-11 Novobiotic Pharmaceuticals Llc Novel macrocyclic polyene lactams
EA021758B1 (ru) * 2008-04-24 2015-08-31 Бристол-Маерс Сквибб Компани Способ лечения болезни альцгеймера
AU2012239977B9 (en) 2011-04-07 2016-11-17 Sloan-Kettering Institute For Cancer Research Migrastatins and uses thereof
WO2013013240A2 (en) * 2011-07-21 2013-01-24 Theracrine, Inc. Macrocyclic compounds and related compositons and methods of use
CN108218932B (zh) * 2017-12-27 2019-01-04 北京大学 凝集素受体介导的癌症预靶向治疗药物
US11187655B2 (en) 2018-05-16 2021-11-30 Sensera, Inc. Compact gas sensors

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2529825A (en) * 1946-12-06 1950-11-14 Firmenich & Co Successeurs De Preparation of cyclic 1, 2-ketols having 10 to 18 carbon atoms in ring
GB989476A (en) * 1963-01-21 1965-04-22 Rhone Poulenc Sa Process for the preparation of cyclic carboxylic acids and their esters
US3227742A (en) * 1960-05-06 1966-01-04 Rhone Poulenc Sa Methyl and ethyl esters of cyclododecanoic and cycloundecanoic acid
JPS5634655A (en) * 1979-08-28 1981-04-06 Haarmann & Reimer Gmbh 33methyllcyclohexadecc33enee11one* its manufacture and use
JPS5634656A (en) * 1979-08-28 1981-04-06 Haarmann & Reimer Gmbh Cyclopentadecc88enee11one* its manufacture and its use
JPS6156146A (ja) * 1984-08-28 1986-03-20 Nippon Mining Co Ltd 大環状ケトンの製造方法
EP0374445A1 (fr) * 1988-12-23 1990-06-27 Firmenich Sa Nouveaux composés cycliques oxygénés, leur utilisation à titre d'ingrédients parfumants, procédé pour leur préparation
JPH07138257A (ja) * 1993-11-16 1995-05-30 Taisho Pharmaceut Co Ltd 骨吸収抑制物質ｂｒ−０４０及びｂｒ−０４２
JP2000178223A (ja) * 1998-09-03 2000-06-27 Givaudan Roure Internatl Sa メチルシクロテトラデカ―５―エン―１―オン類
WO2001046451A1 (en) * 1999-12-22 2001-06-28 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Migrastatin, process for producing the same and medicinal compositions
JP2001521891A (ja) * 1997-10-31 2001-11-13 アボット・ラボラトリーズ 腫瘍および黄斑変性症治療用のマクロライドの使用方法
JP2002519396A (ja) * 1998-07-06 2002-07-02 クエスト・インターナショナル・ビー・ブイ ケトンのアルケンへの付加を利用する大環式ケトンの製造
US20020119937A1 (en) * 2000-08-21 2002-08-29 Chaitan Khosla Fermentation and purification of migrastatin and analog
EP1264594A2 (en) * 2001-06-08 2002-12-11 Takasago International Corporation Melanin production inhibitors and skincare products containing such inhibitors
JP2003171335A (ja) * 2001-12-04 2003-06-20 Japan Energy Corp 大環状ケトン化合物の製造方法
WO2004009380A1 (fr) * 2002-07-23 2004-01-29 Societe De Technologie Michelin Pneumatique avec ancrage non-lineaire de structure de renfort
WO2004083164A1 (ja) * 2003-03-19 2004-09-30 Ube Industries, Ltd. ωーシアノアルデヒド化合物の製造法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1036084A (en) * 1962-02-23 1966-07-13 Upjohn Co Oxygenated cycloalkanes and the preparation thereof
US4472435A (en) * 1980-07-31 1984-09-18 Hoffman-La Roche Inc. Benzophenone derivatives useful in treating heart failure
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
JP2001081088A (ja) 1999-09-10 2001-03-27 Nippon Kayaku Co Ltd 新規生理活性物質ｎｋ３０４２４類縁体とそれらの製造法および用途
JP2001078793A (ja) 1999-09-10 2001-03-27 Nippon Kayaku Co Ltd 新規生理活性物質の醗酵法による製造法
US6660306B2 (en) * 2000-10-12 2003-12-09 Mickey L. Peshoff Wound healing compound
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
JP2004535175A (ja) 2001-04-26 2004-11-25 エコピア バイオサイエンシーズ インク ポリケチド生合成用遺伝子及びタンパク質
JP2003104967A (ja) 2001-09-28 2003-04-09 Takuma Sasaki ウロキナーゼ産生阻害剤、血管新生阻害剤、癌転移抑制剤および抗腫瘍剤
WO2004052359A1 (en) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
US20070037783A1 (en) * 2003-03-28 2007-02-15 Xin-Yun Huang Migrastatin analogs and uses thereof
JP4928937B2 (ja) 2003-03-28 2012-05-09 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ ミグラスタチンアナログおよびその使用
WO2005019181A1 (en) 2003-08-19 2005-03-03 Cornell Research Foundation, Inc. Migrastatin analog cell migration inhibitors
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
CA2582766C (en) * 2004-09-23 2014-07-22 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
WO2009070244A2 (en) 2007-11-21 2009-06-04 Cornell University Methods for inhibiting fascin
WO2010045442A1 (en) 2008-10-15 2010-04-22 Infinity Discovery, Inc. Ansamycin hydroquinone compositions

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2529825A (en) * 1946-12-06 1950-11-14 Firmenich & Co Successeurs De Preparation of cyclic 1, 2-ketols having 10 to 18 carbon atoms in ring
US3227742A (en) * 1960-05-06 1966-01-04 Rhone Poulenc Sa Methyl and ethyl esters of cyclododecanoic and cycloundecanoic acid
GB989476A (en) * 1963-01-21 1965-04-22 Rhone Poulenc Sa Process for the preparation of cyclic carboxylic acids and their esters
JPS5634655A (en) * 1979-08-28 1981-04-06 Haarmann & Reimer Gmbh 33methyllcyclohexadecc33enee11one* its manufacture and use
JPS5634656A (en) * 1979-08-28 1981-04-06 Haarmann & Reimer Gmbh Cyclopentadecc88enee11one* its manufacture and its use
JPS6156146A (ja) * 1984-08-28 1986-03-20 Nippon Mining Co Ltd 大環状ケトンの製造方法
EP0374445A1 (fr) * 1988-12-23 1990-06-27 Firmenich Sa Nouveaux composés cycliques oxygénés, leur utilisation à titre d'ingrédients parfumants, procédé pour leur préparation
JPH07138257A (ja) * 1993-11-16 1995-05-30 Taisho Pharmaceut Co Ltd 骨吸収抑制物質ｂｒ−０４０及びｂｒ−０４２
JP2001521891A (ja) * 1997-10-31 2001-11-13 アボット・ラボラトリーズ 腫瘍および黄斑変性症治療用のマクロライドの使用方法
JP2002519396A (ja) * 1998-07-06 2002-07-02 クエスト・インターナショナル・ビー・ブイ ケトンのアルケンへの付加を利用する大環式ケトンの製造
JP2000178223A (ja) * 1998-09-03 2000-06-27 Givaudan Roure Internatl Sa メチルシクロテトラデカ―５―エン―１―オン類
WO2001046451A1 (en) * 1999-12-22 2001-06-28 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Migrastatin, process for producing the same and medicinal compositions
US20020119937A1 (en) * 2000-08-21 2002-08-29 Chaitan Khosla Fermentation and purification of migrastatin and analog
EP1264594A2 (en) * 2001-06-08 2002-12-11 Takasago International Corporation Melanin production inhibitors and skincare products containing such inhibitors
JP2003171335A (ja) * 2001-12-04 2003-06-20 Japan Energy Corp 大環状ケトン化合物の製造方法
WO2004009380A1 (fr) * 2002-07-23 2004-01-29 Societe De Technologie Michelin Pneumatique avec ancrage non-lineaire de structure de renfort
WO2004083164A1 (ja) * 2003-03-19 2004-09-30 Ube Industries, Ltd. ωーシアノアルデヒド化合物の製造法

Also Published As

Publication number Publication date
EP1608626A1 (en) 2005-12-28
EP1613603A2 (en) 2006-01-11
US8835693B2 (en) 2014-09-16
US8324284B2 (en) 2012-12-04
US7943800B2 (en) 2011-05-17
JP2006521407A (ja) 2006-09-21
JP4719671B2 (ja) 2011-07-06
WO2004087673A2 (en) 2004-10-14
CA2520732A1 (en) 2004-10-14
JP2006523233A (ja) 2006-10-12
WO2004087673A3 (en) 2004-11-04
US20110263653A1 (en) 2011-10-27
US20140011844A1 (en) 2014-01-09
WO2004087672A1 (en) 2004-10-14
JP2011105766A (ja) 2011-06-02
US8202911B2 (en) 2012-06-19
US20110281916A1 (en) 2011-11-17
CA2520732C (en) 2012-12-04
WO2004087673B1 (en) 2005-03-10
US20070037852A1 (en) 2007-02-15
CA2520377A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
JP2011105766A (ja) ミグラスタチンアナログ組成物およびその使用
JP2008273981A (ja) 癌の処置におけるマイグラスタチンアナログ
US20240294540A1 (en) Biologically Active Taxane Analogs and Methods of Treatment by Oral Administration
EP0708642B1 (en) Taxol derivatives
JP2004500388A (ja) エポチロン、その中間体およびその類似体の合成
JP5970536B2 (ja) タキサンおよびアベオ−タキサン類似体
US20070037783A1 (en) Migrastatin analogs and uses thereof
US8188141B2 (en) Isomigrastatin analogs in the treatment of cancer
JP2002535276A (ja) ４−デメチルペンクロメジンのアシル誘導体、その使用及び調製
US11873308B2 (en) Biologically active taxane analogs and methods of treatment by oral administration
CA3102497A1 (en) Open-ring fatty acid compound having anti-cancer activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100823

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101025

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111114

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120213

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150217

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees